Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Crizotinib
Related studies linked through entity extraction aliases.
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
- Status
- TERMINATED
- Phase
- PHASE2
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
- Status
- COMPLETED
- Phase
- PHASE3
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Dasatinib and Crizotinib in Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
- Status
- COMPLETED
- Phase
- PHASE1
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE3
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1